William M. Rosenberg OR W. Rosenberg OR W.M.C Rosenberg OR William Rosenberg OR W.M. Rosenberg
William M. Rosenberg OR W. Rosenberg OR W.M.C Rosenberg OR William Rosenberg OR W.M. Rosenberg
UCL and The Royal Free London NHS Foundation Trust
Verified email at
Cited by
Cited by
Evidence based medicine: what it is and what it isn't
DL Sackett, WMC Rosenberg, JAM Gray, RB Haynes, WS Richardson
Bmj 312 (7023), 71-72, 1996
Evidence-based medicine
DL Sackett
Seminars in perinatology 21 (1), 3-5, 1997
Evidence based medicine: an approach to clinical problem-solving
W Rosenberg, A Donald
Bmj 310 (6987), 1122-1126, 1995
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017
EASL Clinical Practice Guidelines: management of hepatitis C virus infection
European Association For The Study Of The Liver
Journal of hepatology 55 (2), 245-264, 2011
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection
SI Khakoo, CL Thio, MP Martin, CR Brooks, X Gao, J Astemborski, ...
Science 305 (5685), 872-874, 2004
Serum markers detect the presence of liver fibrosis: a cohort study
WMC Rosenberg, M Voelker, R Thiel, M Becka, A Burt, D Schuppan, ...
Gastroenterology 127 (6), 1704-1713, 2004
On the need for evidence-based medicine
DL Sackett, WMC Rosenberg
Journal of Public Health 17 (3), 330-334, 1995
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
GR Foster, N Afdhal, SK Roberts, N Bršu, EJ Gane, S Pianko, E Lawitz, ...
New England Journal of Medicine 373 (27), 2608-2617, 2015
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document
SA Khan, BR Davidson, R Goldin, SP Pereira, WMC Rosenberg, ...
Gut 51 (suppl 6), vi1-vi9, 2002
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ...
Hepatology 47 (2), 455-460, 2008
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
SA Khan, BR Davidson, RD Goldin, N Heaton, J Karani, SP Pereira, ...
Gut 61 (12), 1657-1669, 2012
EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B: 13–14 September, 2002 Geneva, Switzerland Consensus statement (Long version)
TE Jury
Journal of Hepatology 39, 3-25, 2003
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ...
Journal of viral hepatitis 21, 34-59, 2014
Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants
P Klenerman, S Rowland-Jones, S McAdam, J Edwards, S Daenke, ...
Nature 369 (6479), 403-407, 1994
Medicina basada en la evidencia
DL Sackett, WS Richardson, W Rosenberg, RB Haynes
Elsevier Espana, 2000
Historical epidemiology of hepatitis C virus (HCV) in selected countries
P Bruggmann, T Berg, ALH ōvrehus, C Moreno, CE Brand„o Mello, ...
Journal of viral hepatitis 21, 5-33, 2014
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease
J Parkes, P Roderick, S Harris, C Day, D Mutimer, J Collier, M Lombard, ...
Gut 59 (9), 1245-1251, 2010
Genetics of inflammatory bowel disease.
J Satsangi, DP Jewell, WM Rosenberg, JI Bell
Gut 35 (5), 696, 1994
Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide.
PA Moss, RJ Moots, WM Rosenberg, SJ Rowland-Jones, HC Bodmer, ...
Proceedings of the National Academy of Sciences 88 (20), 8987-8990, 1991
The system can't perform the operation now. Try again later.
Articles 1–20